2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias
K Ono, Y Iwasaki, M Akao, T Ikeda, K Ishii… - Circulation …, 2022 - jstage.jst.go.jp
The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …
Stroke prevention in atrial fibrillation
B Freedman, TS Potpara, GYH Lip - The Lancet, 2016 - thelancet.com
Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial
fibrillation monitoring. Data from stroke registries show that both unknown and untreated or …
fibrillation monitoring. Data from stroke registries show that both unknown and untreated or …
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …
Objective To study the effectiveness and safety of the non-vitamin K antagonist oral
anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban …
anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban …
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …
[HTML][HTML] Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management
Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and
direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in …
direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in …
Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017
Objective Since 2010, several non–vitamin K antagonist oral anticoagulants (NOACs) have
been brought to the US market, yet little is known regarding their evolving adoption for …
been brought to the US market, yet little is known regarding their evolving adoption for …
[HTML][HTML] Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative …
S Ballestri, E Romagnoli, D Arioli, V Coluccio… - Advances in …, 2023 - Springer
Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …
with a significant healthcare burden, and represent the main indications for anticoagulation …
Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation
BK Martinez, NA Sood, TJ Bunz… - Journal of the American …, 2018 - Am Heart Assoc
Background Frailty predicts poorer outcomes and decreased anticoagulation use in patients
with nonvalvular atrial fibrillation. We sought to assess the effectiveness and safety of …
with nonvalvular atrial fibrillation. We sought to assess the effectiveness and safety of …